• Has over 30 years' experience in drug R&D

• Served as senior research scientist at Gilead Sciences, Inc.

• Served as associate director of chemical research at Pharmasset Inc.

• During his career at Pharmasset, Dr. Du, as one of the inventors, participated in the R&D of sofosbuvir (also known as sovaldi), a revolutionary drug for treating hepatitis C which won the Prix Galien Award granted by the Galien Foundation in 2014(the equivalent of the Nobel Prize in biopharmaceutical research)

• In Jan. 2012, Gilead Sciences, Inc. completed the acquisition of Pharmasset Inc. for about USD 11.2 billion, and  thereby obtained sofosbuvir

• Has published 60 academic papers and participated in the invention of more than 300 patents registered worldwide, of which 42 patents had been licensed in the United States

• Has over 30 years of experience in R&D, BD and management in the biopharmaceutical industry

• Served as the vice president of CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., a wholly owned subsidiary of CSPC Pharmaceutical Group Limited, and the vice president of Qilu Pharmaceutical Co., Ltd.

• Served as the Asia head of external innovation for endocrine and cardiovascular system at the Lilly China R&D Center of Eli Lilly and Company

• Served as director of foreign cooperative chemical projects at Merck Sharp & Dohme Corp. and director of medicinal chemistry at Metabasis Therapeutics, Inc.

• Participated in the R&D of various drugs and drug candidates for clinical use, including a first generation and a second generation FBPase inhibitor for the treatment of type II diabetes

• Has nearly 30 years of experience in pharmacology research, particularly in oncology, led or supported multiple NDA programs for innovative drugs, most notably Loncastuximab tesirine, a CD-19 ADC for lymphoma, Abivertinib, an EGFR inhibitor for lung cancer, Erdafitinib, an FGFR inhibitor for urothelial cancer, and Dasatinib, a BCR-ABL inhibitor for leukemia

• Received his doctor degree from the University of North Carolina at Chapel Hill and completed his postdoctoral clinical fellowship training at Cancer Institute of New Jersey

• Held key leadership positions in various famous pharmaceutical enterprises including Johnson & Johnson, with a wealth of experience in translational research, clinical development and executive management

• Has over 30 years of experience in clinical medicine and basic medical research

• Served at the University of Virginia Health System in the United States, responsible for medical research and clinical practice

• Served as a physician and director of the International Medical Center at Shenzhen VISTA-SK International Medical Co., Ltd.

• Obtained the National Institutes of Health (NIH) RO1 Research Project Grant in 2003

• Published many high-quality academic papers in international authoritative academic journals and holds multiple invention patents

• Nearly 25 years of experience in innovative drug R&D; with extensive expertise in novel drug development

• Former Vice General Manager at Shanghai Yishi Medical Technology Co., Ltd., a subsidiary of CSPC Pharmaceutical Group Limited

• Former Executive Officer of the Medicinal Chemistry Department at Adlai Nortye Biopharma Co., Ltd.

• Served as Research Fellow at Vertex, U.S., for 17 years, where he played a leading role in the R&D of 7 preclinical/clinical drug candidates and contributed in 5 "First-in-Class" new drug projects